Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr 10;2(1):e000236.
doi: 10.1136/openhrt-2014-000236. eCollection 2015.

Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?

Flávio Danni Fuchs  1 , James J DiNicolantonio  2
Affiliations
Review

Angiotensin receptor blockers for prevention of cardiovascular disease: where does the evidence stand?

Flávio Danni Fuchs et al. Open Heart. .

Abstract

Angiotensin receptor blockers (ARBs) are the most commonly used among blood pressure-lowering drugs worldwide, despite the absence of sound evidence of effectiveness in large and unbiased clinical trials. Meta-analyses published in recent years and reviewed here have not given support to this preference, suggesting that ARBs may be ineffective in the prevention of all cause mortality and major cardiovascular events (particularly myocardial infarction). There is evidence that ARB can be harmful for the kidney, particularly in patients with diabetes and in the elderly. It may be time to call for a moratorium on the preference for ARB in the management of hypertension and in patients with high cardiovascular risk.

PubMed Disclaimer

References

    1. Fuchs FD. The role of angiotensin receptor blockers in the prevention of cardiovascular and renal disease: time for reassessment? Evid Based Med 2013;18:44–7. 10.1136/eb-2012-100851 - DOI - PubMed
    1. Lithell H, Hansson L, Skoog I et al. . The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–86. 10.1097/00004872-200305000-00011 - DOI - PubMed
    1. Yusuf S, Teo K, Anderson C et al. , Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008;372:1174–83. 10.1016/S0140-6736(08)61193-9 - DOI - PubMed
    1. Yusuf S, Diener HC, Sacco RL et al. , PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225–37. 10.1056/NEJMoa0804593 - DOI - PMC - PubMed
    1. McMurray JJ, Holman RR, Haffner SM et al. , NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1477–90. 10.1056/NEJMcp0909392 - DOI - PubMed

Publication types

LinkOut - more resources